Kilitch Drugs (India) Limited has informed the Exchange about Copy of Newspaper Publication
KILITCH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kilitch Drugs has submitted copies of newspaper publications of its unaudited financial results for the quarter ended 30 June 2025 (Q1 FY26) to BSE and NSE, published in Marathi and English editions on 15 August 2025 as required under SEBI LODR regulations. The Board had approved these results on 13 August 2025. Key consolidated highlights: total income from operations stood at Rs 4,313.98 lakhs vs Rs 3,345.16 lakhs in Q1 FY25, net profit after tax jumped to Rs 226.25 lakhs from Rs 11.19 lakhs YoY, and EPS rose to Rs 1.88 from Rs 0.83. On a standalone basis, revenue was Rs 3,412.20 lakhs and profit after tax was Rs 479.41 lakhs (vs Rs 405.40 lakhs YoY).
This is a routine regulatory compliance filing and should not move the stock on its own. However, the underlying numbers show strong year-on-year profit growth, which is mildly positive for shareholders and could reinforce sentiment around the stock.